NewsBenzingaJohnson & Johnsons Icotrokinra-Hydrochlorid erhält die Zulassung der Medicines and Healthcare Products Regulatory Agency zur Behandlung von mittelschwerer bis schwerer Plaque-Psoriasis Johnson & Johnsons Icotrokinra-Hydrochlorid erhält die Zulassung der Medicines and Healthcare Products Regulatory Agency zur Behandlung von mittelschwerer bis schwerer Plaque-Psoriasis Benzinga 2026.10.23 14:27 (GMT+0) Open on Benzinga Other news Citigroup Maintains Neutral on Texas Roadhouse, Lowers Price Target to $189 Citigroup Maintains Buy on Sweetgreen, Raises Price Target to $13 Citigroup Maintains Neutral on Bloomin Brands, Lowers Price Target to $12.25 Citigroup Maintains Neutral on BJ's Restaurants, Lowers Price Target to $70 Crude Oil Surges 4%; SLB Shares Jump Following Upbeat Q3 Earnings OpenAI Says It Expects That Future Models Will Be Able To Identify & Exploit Vulnerabilities Of Which It Is Not Yet Aware
OpenAI Says It Expects That Future Models Will Be Able To Identify & Exploit Vulnerabilities Of Which It Is Not Yet Aware
